Latest News and Press Releases
Want to stay updated on the latest news?
-
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company...
-
15 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Receipt of NASDAQ Delisting DeterminationPlans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
-
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting and General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
-
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
-
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
-
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...
-
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
-
28 April 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2022 Biodexa Pharmaceuticals...